Abcam, ab258869, Human FAM83D knockout HEK-293T cell lysate

Size: 1Kit
FAM83D KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-FAM83D, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FAM83D also known as Family with Sequence Similarity 83 Member D is an important protein involved in cellular processes. It is a protein of significant mass approximately 68 kDa and is highly expressed in the nucleus of proliferating cells. FAM83D's role is associated with cell cycle regulation and it functions effectively in maintaining proper chromosome segregation during mitosis. The protein shows higher expression in rapidly dividing tissues suggesting a link to cell division and growth mechanisms.
Biological function summary
FAM83D participates in vital cellular functions related to mitosis and cancer cell proliferation. It does not function alone but is part of the spindle assembly complex ensuring proper mitotic spindle formation and stability. These interactions highlight its importance in maintaining genomic integrity during cell division reducing the potential for errors that can lead to tumorigenesis. The involvement in this complex makes FAM83D an attractive target for studying cancer biology.
Pathways
FAM83D interacts closely with several key proteins governing cell cycle progression including the Aurora kinase pathway and the Plk1 pathway. It plays a role in phosphorylating and activating proteins necessary for mitotic entry and progression. FAM83D's interaction with Aurora B kinase is particularly critical as it contributes to proper chromosomal alignment and segregation linking it to important regulatory mechanisms in cell proliferation.
Aberrant expression of FAM83D contributes to cancer development including breast cancer and colorectal cancer. Abnormal FAM83D levels disrupt normal cell cycle regulation leading to uncontrolled cell growth. Additionally its interaction with cancer-related proteins such as Cyclin B1 highlights its significance in malignant cells offering potential pathways for therapeutic intervention. Understanding FAM83D's roles and relationships may offer insight into diagnostic and treatment strategies for these cancers.